Young Tae Kim and Min Zhao development and in neoplasia. Proc Natl Acad Sci USA 2001;98:13138-43. 73. Dirks PB, Rutka JT. Current concepts in neuro-onco- logy: the cell cycle a review. Neurosurgery 1997;40: 1000-15. 74. Quade BJ, Park JJ, Crum CP, Sun D, Dutta A. In vivo cyclin E expression as a marker for early cervical neoplasia. Mod Pathol 1998;11:1238-46. 75. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. Inactivation of the CDK inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996;13:2323-30. 76. Southern SA, McDicken IW, Herrington CS. Loss of cytokeratin 14 expression is related to human papillo- mavirus type and lesion grade in squamous intraepi- thelial lesions of the cervix. Hum Pathol 2001;32:1351-5. 77. Southern SA, McDicken IW, Herrington CS. Evidence for keratinocyte immortalization in high-grade squa- mous intraepithelial lesions of the cervix infected with high-risk human papillomaviruses. Lab Invest 2000;80: 539-44. 78. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, et al. Ki-67, cyclin E, and p16INK4 are com- plimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25:884-91. 79. Kanai M, Shiozawa T, Xin L, Nikaido T, Fujii S. Immu- nohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix. Cancer 1998;82:1709-19. 80. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catas- trophe: a molecular definition. Oncogene 2004;23:2825- 37. 81. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992;257:1958-61. 82. Harbour JW, Dean DC. Rb function in cell-cycle regula- tion and apoptosis. Nat Cell Biol 2000;2:E65-7. 83. Jones DL, Alani RM, Munger K. The human papilloma- virus E7 oncoprotein can uncouple cellular differentia- tion and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997;11:2101-11. 84. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45. 85. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-25. 86. Kanao H, Enomoto T, Ueda Y, Fujita M, Nakashima R, Ueno Y, et al. Correlation between p14(ARF)/p16 (INK4A) expression and HPV infection in uterine cervical cancer. Cancer Lett 2004;213:31-7. 87. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000. Yonsei Med J Vol. 46, No. 5, 2005 88. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34. 89. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14. 90. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, Riethdorf L, Loning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV- positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439:55-61. 91. Brooks LA, Sullivan A, O'Nions J, Bell A, Dunne B, Tidy JA, et al. E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br J Cancer 2002;86:263-8. 92. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuro- blastoma and other human cancers. Cell 1997;90:809- 19. 93. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45. 94. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13:4107-14. 95. Dellas A, Schultheiss E, Almendral AC, Gudat F, Oberholzer M, Feichter G, et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer 1997;74:421-5. 96. Cheng YT, Li YL, Wu JD, Long SB, Tzai TS, Tzeng CC, et al. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines. Mol Carcinog 1995;13:173-81. 97. Skomedal H, Kristensen GB, Nesland JM, Borresen- Dale AL, Trope C, Holm R. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus. J Pathol 1999;187:556-62. 98. Ikenberg H, Matthay K, Schmitt B, Bauknecht T, Kiechle-Schwarz M, Goppinger A, et al. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer 1995; 76:57-66. 99. Troncone G, Martinez JC, Palombini L, De Rosa G, Mugica C, Rodriguez JA, et al. Immunohistochemical expression of mdm2 and p21WAF1 in invasive cervical cancer: correlation with p53 protein and high risk HPV infection. J Clin Pathol 1998;51:754-60. 100. Oka K, Suzuki Y, Nakano T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer 2000;88:2766-73.